Zonula Occludens Toxin Acts as an Adjuvant through Different Mucosal Routes and Induces Protective Immune Responses
- 1 April 2003
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 71 (4) , 1897-902
- https://doi.org/10.1128/iai.71.4.1897-1902.2003
Abstract
Zonula occludens toxin (Zot) is produced by Vibrio cholerae and has the ability to increase mucosal permeability by reversibly affecting the structure of tight junctions. Because of this property, Zot is a promising tool for mucosal drug and antigen (Ag) delivery. Here we show that Zot acts as a mucosal adjuvant to induce long-lasting and protective immune responses upon mucosal immunization of mice. Indeed, the intranasal delivery of ovalbumin with two different recombinant forms of Zot in BALB/c mice resulted in high Ag-specific serum immunoglobulin G titers that were maintained over the course of a year. Moreover, His-Zot induced humoral and cell-mediated responses to tetanus toxoid in C57BL/6 mice and protected the mice against a systemic challenge with tetanus toxin. In addition, we found that Zot also acts as an adjuvant through the intrarectal route and that it has very low immunogenicity compared to the adjuvant Escherichia coli heat-labile enterotoxin. Finally, by using an octapeptide representing the putative binding site of Zot and of its endogenous analogue zonulin, we provide evidence that Zot may bind a mucosal receptor on nasal mucosa and may mimic an endogenous regulator of tight junctions to deliver Ags in the submucosa. In conclusion, Zot is a novel and effective mucosal adjuvant that may be useful for the development of mucosal vaccines.Keywords
This publication has 35 references indexed in Scilit:
- Intestinal zonulin: open sesame!Gut, 2001
- Zonula Occludens Toxin Structure-Function AnalysisJournal of Biological Chemistry, 2001
- Purification and preliminary characterization of the zonula occludens toxin receptor from human (CaCo2) and murine (IEC6) intestinal cell linesFEMS Microbiology Letters, 2001
- Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model.Journal of Clinical Investigation, 1997
- Oral but Not Parenteral Interleukin (IL)-12 Redirects T Helper 2 (Th2)-type Responses to an Oral Vaccine Without Altering Mucosal IgA ResponsesThe Journal of Experimental Medicine, 1997
- Lysogenic Conversion by a Filamentous Phage Encoding Cholera ToxinScience, 1996
- Mechanisms for Mucosal Immunogenicity and Adjuvancy of Escherichia coli Labile EnterotoxinThe Journal of Infectious Diseases, 1996
- Mucosal immunity to infection with implications for vaccine developmentCurrent Opinion in Immunology, 1994
- Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions.Proceedings of the National Academy of Sciences, 1991
- Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTBVaccine, 1989